Better Health for All

VYNE Therapeutics Inc. is entirely focused on developing therapies for autoimmune and inflammatory conditions, with all pipeline products (VYN201, VYN202, FMX114) targeting health improvement. VYN202 showed up to a 90% reduction in PASI scores in a small psoriasis cohort, and VYN201 demonstrated a 40.8% median reduction in MMP-9 for vitiligo.

The company is clinical-stage and has no revenue from products with negative health outcomes. However, the FDA placed a clinical hold on VYN202's Phase 1b trial in April 2025 due to non-clinical toxicity findings in dogs, which was partially lifted in July 2025 for female patients at lower doses, but the psoriasis study was discontinued. The Phase 2b trial for Repibresib gel in vitiligo reported a higher rate of treatment-emergent adverse events (TEAEs) for subjects receiving the gel compared to vehicle, with application site pain being the most frequent (up to 14.0% for Repibresib 3% vs. 3.8% for vehicle). Eight subjects discontinued due to an AE in the Repibresib group compared to none in the vehicle group. The company's R&D expense for the nine months ended September 30, 2025, was $16.2 million, against an estimated R&D budget of $70 million for 2025, representing 23.1% of the budget. The Inflation Reduction Act (IRA) is noted as expanding government negotiation for high-cost drugs, and VYNE will need to anticipate and address access concerns, with 80% of autoimmune patients being women. The company provides a specific privacy notice to clinical trial participants and adheres to HIPAA and FDA GCP guidelines. The company's operations generate limited health-harming externalities, with new EPA rules impacting chemical waste management.

Fair Trade & Ethical Sourcing

No quantitative data related to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend was found in the provided articles.

The articles primarily consist of company codes of conduct, compliance programs, and general ESG statements, which outline policies and commitments but do not provide specific performance metrics or verifiable actions for the supply chain.

Honest & Fair Business

VYNE Therapeutics has a formal whistleblower policy with a secure web form and hotline for confidential and anonymous submission of concerns regarding accounting, internal controls, or auditing matters.

A 14-16 digit code is provided for tracking complaint status, and the hotline reports to the Audit Committee Chairperson and General Counsel. However, non-employees must disclose their identity, and there is no explicit evidence of independent investigation processes. The company has an anti-corruption policy that prohibits bribery, kickbacks, and illegal payments to government officials, outlining 'facilitating' payment exceptions requiring CEO approval. It also expects vendors to comply with the Foreign Corrupt Practices Act (FCPA) and has a zero-tolerance policy for bribery and corruption. Independent auditors are engaged to review financial statements and report to the board, and the Audit Committee oversees the independent audit function, but the extent of this verification beyond financial statements is not specified.

Kind to Animals

The company conducts non-clinical toxicology studies using dogs for drug development, which led to reported testicular toxicity and a clinical hold on a Phase 1b trial for VYN202.

There is no explicit information regarding the company's animal testing policy, the volume of animals used, or any investment in animal-free alternatives. While the company is working with the FDA to resolve the clinical hold, there is no evidence of public policy engagement related to broader animal welfare legislation or industry standards.

Planet-Friendly Business

VYNE Therapeutics Inc. does not have publicly available carbon emissions data or specific reduction targets.

The company is not participating in any tracked initiatives related to carbon emissions reduction or climate pledges. No specific quantitative data is provided regarding environmental metrics such as renewable energy use, water use, or waste diversion. There is also no information available on regulatory actions, violations, fines, or compliance issues related to environmental performance.

Respect for Cultures & Communities

The provided article from vynetx.com focuses on VYNE Therapeutics' pipeline, stock, news, and career opportunities.

It explicitly states that it does not contain any data relevant to cultural sensitivity or community engagement. Therefore, no evidence is available to score any of the KPIs for Respect for Cultures & Communities.

Zero Waste & Sustainable Products

VYNE Therapeutics Inc. has implemented a waste reduction initiative focused on paper, saving an estimated 170+ million sheets annually across its Vyne Medical and Vyne Dental customers.

This effort eliminates the need to harvest the equivalent of 11,000 trees each year. While the company states a commitment to broader waste reduction, greener infrastructure, and sustainable suppliers, no specific quantitative data or metrics for these additional initiatives are provided.